Benzodiazepines for alcohol withdrawal
|
|
- Elfreda Hardy
- 8 years ago
- Views:
Transcription
1 [Intervention Review] Benzodiazepines for alcohol withdrawal Christos Ntais 1, Emilios Pakos 2, Panayiotis Kyzas 2, John PA Ioannidis 3 1 Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece. 2 Department of Hygiene and Epidemiology, University of Ioannina, Ioannina, Greece. 3 Department of Hygiene and Epidemiology, Evidence-based Medicine Unit, University of Ioannina School of Medicine, Ioannina, Greece Contact address: Christos Ntais, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, 14 Ch Zoidi st, Ioannina, GR45444, Greece. md02802@cc.uoi.gr. (Editorial group: Cochrane Drugs and Alcohol Group.) Cochrane Database of Systematic Reviews, Issue 1, 2009 (Status in this issue: Unchanged) DOI: / CD pub2 This version first published online: 20 July 2005 in Issue 3, Last assessed as up-to-date: 18 May (Help document - Dates and Statuses explained) This record should be cited as: Ntais C, Pakos E, Kyzas P, Ioannidis JPA. Benzodiazepines for alcohol withdrawal. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD DOI: / CD pub2. Background A B S T R A C T Alcohol withdrawal syndrome is a cluster of symptoms that occurs in alcohol-dependent people after cessation or reduction in alcohol use. This systematic review focuses on the evidence of benzodiazepines use in the treatment of alcohol withdrawal symptoms. Objectives To evaluate the effectiveness and safety of benzodiazepines in the treatment of alcohol withdrawal. Search strategy We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 4, 2004), MEDLINE (1966 to October 2004) and EU-PSI PSI-Tri database with no language and publication restrictions. We also screened references of retrieved articles. Selection criteria All randomised controlled trials examining the effectiveness and safety of a benzodiazepine in comparison with a placebo or other pharmacological intervention or other benzodiazepine were considered. Data collection and analysis Two reviewers independently assessed trial quality and extracted data. Main results Fifty-seven trials, with a total of 4,051 people were included. Despite the considerable number of randomized controlled trials, there was a very large variety of outcomes and of different rating scales and relatively limited quantitative synthesis of data was feasible. Benzodiazepines offered a large benefit against alcohol withdrawal seizures compared to placebo (relative risk [RR] 0.16; 95% confidence interval [CI] 0.04 to 0.69; p = 0.01). Benzodiazepines had similar success rates as other drugs (RR 1.00; 95% CI 0.83 to 1.21) or anticonvulsants in particular (RR 0.88; 95% CI 0.60 to 1.30) and offered a significant benefit for seizure control against nonanticonvulsants (RR 0.23; 95% CI 0.07 to 0.75; p = 0.02), but not against anticonvulsants (RR 1.99; 95% CI 0.46 to 8.65). Changes in Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scores at the end of treatment were similar with benzodiazepines versus other drugs, although some small studies showed isolated significant differences for other, less commonly, used scales. Data on other comparisons were very limited, thus making quantitative synthesis for various outcomes not very informative. 1
2 Authors conclusions Benzodiazepines are effective against alcohol withdrawal symptoms, in particular seizures, when compared to placebo. It is not possible to draw definite conclusions about the relative effectiveness and safety of benzodiazepines against other drugs in alcohol withdrawal, because of the large heterogeneity of the trials both in interventions and assessment of outcomes but the available data do not show prominent differences between benzodiazepines and other drugs in success rates. P L A I N L A N G U A G E S U M M A R Y Benzodiazepines are more effective than placebo against alcohol withdrawal seizures while they have variable profile against other commonly used treatments This Cochrane review summarizes evidence from fifty-seven randomised controlled trials evaluating the effectiveness and safety of benzodiazepines in the treatment of alcohol withdrawal symptoms. The available data show that benzodiazepines are effective against alcohol withdrawal seizures when compared to placebo. However, there are no prominent differences between benzodiazepines and other drugs in success rates. Data on safety outcomes are sparse and fragmented. There is a need for larger, well-designed studies in this field. 2
3 B A C K G R O U N D Alcohol abuse and dependence represents a most serious health problem worldwide with major social, interpersonal and legal interpolations. Dependence on alcohol is associated with both physiological symptoms such as tolerance and withdrawal, and behavioral symptoms such as impaired control over drinking (Hasin 1990). Alcohol withdrawal syndrome is a cluster of symptoms that occurs in alcohol-dependent people after cessation or reduction in alcohol use that has been heavy or prolonged. The clinical presentation varies from mild to serious and the onset of symptoms typically occurs a few hours after the last alcohol intake. The most common manifestations are tremor, restlessness, insomnia, nightmares, paroxysmal sweats, tachycardia, fever, nausea, vomiting, seizures, hallucinations (auditory, visual, tactile), increased agitation, and tremulousness. A minority of patients develop very severe alcohol withdrawal syndrome, including delirium tremens. These symptoms involve a wide range of neurotransmitter circuits that are implicated in alcohol tolerance and reflect a homeostatic readjustment of the central nervous system (De Witte 2003; Hall 1997; Koob 1997; Nutt 1999; Slawecki 1999). Long-term alcohol consumption affects brain receptors that undergo adaptive changes in an attempt to maintain normal function. Some of the key changes involve reduced brain gamma-aminobutyric acid (GABA) levels and GABA - receptor sensitivity (Dodd 2000; Gilman 1996; Kohl 1998; Petty 1993) and activation of glutamate systems (Tsai 1995), which leads to nervous system hyperactivity in the absence of alcohol. The advances in knowledge of neurobiology and neurochemistry have prompted the use of drugs in the treatment of alcohol dependence and withdrawal that act through these GABA pathways. Benzodiazepines in particular have been widely used for the treatment of alcohol withdrawal symptoms. An early meta-analysis of studies concerning pharmacological therapies of alcohol withdrawal (Mayo-Smith 1997) has suggested that benzodiazepines are effective in reducing withdrawal severity, incidence of delirium and seizures with a greater margin of safety and lower abuse potential when compared to other therapies. A more recent systematic review (Holbrook 1999) of randomised controlled trials (RCTs) comparing benzodiazepines to placebo or other therapy reached similar conclusions. However a large amount of evidence of benzodiazepine use has been published during the last years and it is important that an up-to-date systematic review is performed. Moreover not all patients may need pharmacological treatment and it is unknown whether different benzodiazepines and different regimens of administration (e.g. fixed versus symptom-triggered schedule) may have the same merits. The purpose of this systematic review was to examine the evidence on the effectiveness and safety of benzodiazepines in the management of alcohol withdrawal. O B J E C T I V E S The objectives of this systematic review were: (1) to evaluate the effectiveness of benzodiazepines in the treatment of alcohol withdrawal; (2) to evaluate the safety (potential harms) of benzodiazepines in the treatment of alcohol withdrawal. M E T H O D S Criteria for considering studies for this review Types of studies RCTs examining the effectiveness, safety and overall risk-benefit of a benzodiazepine in comparison to a placebo or other pharmacological intervention or another benzodiazepine in the treatment of alcohol withdrawal were considered. Non-randomized trials were excluded from this systematic review and meta-analysis. Types of participants We considered all patients with alcohol dependence diagnosed with appropriate standardized criteria (e.g. Diagnostic and Statistical Manual of Mental Disorders [DSM] criteria or equivalent) who experienced alcohol withdrawal regardless of the severity of the clinical manifestations (e.g. regardless of Clinical Institute Withdrawal Assessment for Alcohol [CIWA-Ar] score before treatment). All patients were included regardless of age, gender, nationality, and inpatient or outpatient setting. The history of previous treatments was considered, but it was not an eligibility criterion. Types of interventions All RCTs were considered that compare: (1) benzodiazepine versus placebo; (2) benzodiazepine versus other drug; (3) different benzodiazepines among themselves; (4) benzodiazepine combined with other drug versus that other drug; (5) fixed versus symptom-triggered schedule of a benzodiazepine. Types of outcome measures Information was collected on standardized forms for each treatment arm on a variety of outcomes. These included: Primary outcomes Severity of overall alcohol withdrawal syndrome as measured in prespecified scales (including CIWA-Ar 3
4 score, total severity assessment, the doctor s or patient s global assessment, therapeutic success (relief from alcohol withdrawal symptoms, and the doctor s or patient s global assessment of efficacy). For comparisons where there were non-overlapping studies that examined therapeutic success, global improvement (by doctor) or global improvement (by patient), we also examined the outcome of any success at the end of treatment using data on global improvement (by doctor) when therapeutic success data were not available and data on global improvement (by patient) when neither therapeutic success nor global improvement (by doctor) were available. This outcome allows the combination of information from more studies, using data on outcomes that are fairly comparable Alcohol withdrawal seizures Alcohol withdrawal delirium (2) Secondary outcomes Number of patients presenting side effects (with emphasis on severe, life-threatening, and serious events) Discontinuations due to side effects Number of withdrawals per arm Mortality Combined scores for psychiatric symptoms (illusions, hallucinations, clouding of sensorium, quality of contact) Combined scores for neurologic symptoms (tremor, agitation, headache) Combined scores for autonomic symptoms (paroxysmal sweats, flushing of face, nausea, vomiting, other gastrointestinal symptoms) Combined psychological measures of successful treatment (anxiety measures, depressive symptoms) Combined social measures of successful treatment (medical problems, legal problems, social and family relations, employment related problems) Quality of life Quality of sleep Cost of treatment Search methods for identification of studies Electronic searches We used detailed search strategies to identify the studies included in this review, with no language restriction. We searched:cochrane Central Register of Controlled Trials (CENTRAL - The Cochrane Library 4, 2004), MEDLINE database (OVID January 1966 to October 2004),see Appendix 1; Appendix 2. EU-PSI PSI- Tri database was also searched for additional relevant trials ( Manual searches In addition to searching the reference lists of retrieved studies, we handsearched reviews. We also contacted experts in the field wherever possible to find out if they knew of any other published or unpublished controlled trials. Data collection and analysis Study selection Two authors independently screened the titles and abstracts of all publications, which were obtained by the search strategy. We obtained all potentially eligible studies as full articles and two authors independently assessed these for inclusion. In doubtful or controversial cases, the authors discussed all identified discrepancies and reached consensus on all items. If consensus was still not reached, they referred to a third author to solve the problem. Experts familiar to the language managed potential language problems in retrieved studies. We accepted all randomised trials of benzodiazepines in alcohol withdrawal regardless of type of benzodiazepine treatment, daily and total benzodiazepine dose, duration of therapy and type of therapy (inpatient, outpatient). Whenever reports pertained to overlapping patients, we retained only the largest study, to avoid duplication of information. However, we retained studies that involved patients with previously published data on different outcomes. Assessment of the methodological quality In order to limit bias, gain insight into potential comparisons and guide interpretation of findings, two authors, used the criteria described in the Cochrane Reviewers Handbook Alderson 2004, to assess the methodological quality of the eligible studies. Factors that warrant assessment are those related to applicability of findings, validity of individual studies, and certain design characteristics that may affect interpretation of the results. In the context of a systematic review, the validity of a study is the extent to which its design and conduct are likely to prevent systematic errors, or bias (Moher 1995). There are four sources of systematic bias in trials of the effects of healthcare: selection bias, performance bias, attrition bias, and detection bias. All of them were described in each eligible trial. Selection bias Judging the studies on the method of allocation concealment performed as an evaluation of selection bias, authors indicated whether allocation concealment was adequate (A), unclear (B), inadequate (C), or that allocation concealment was not used (D) (Schulz 1995): A. Low risk of bias: adequate allocation concealment, i.e. central randomisation (e.g. allocation by a central office unaware of subject characteristics), pre-numbered or coded identical bottles or containers which are administered serially to participants, drug prepared by the pharmacy, serially numbered, opaque, sealed envelopes, on-site computer system combined with allocations kept in a locked unreadable computer file that can be accessed only after the characteristics of an enrolled participant have been entered or other description that contained elements 4
5 convincing of concealment; B. Moderate risk of bias: unclear allocation concealment, in which the authors either did not report an allocation concealment approach at all or report an approach that did not fall in the category A or C; C. High risk of bias: inadequate allocation concealment, such as alternation or reference to case numbers, dates of birth, day of the week. Any procedure that is entirely transparent before allocation, such as an open list of random numbers or other description that contained elements convincing of not concealment; D. This score refers to studies in which the investigators have not used allocation concealment, i.e. for studies which are not randomised. Performance bias When examining performance bias, the authors considered the use of blinding as a criterion for validity. This could be assessed by the following questions: Were the recipients of care unaware of their assigned intervention? Were those providing care unaware of the assigned intervention? Attrition bias Attrition bias refers to systematic differences between the comparison groups in the loss of participants from the study. Due to inadequacies in reporting how losses of participants (e.g. withdrawals, dropouts, protocol deviations) were handled, the authors were cautious about implicit accounts of follow-up. What is reported in study reports on attrition after allocation has not been found to be consistently related to bias (Schulz 1995). Thus, authors did not use the reported follow-up as a validity criterion. Detection bias Detection bias refers to systematic differences between the comparison groups in outcome assessment. Authors considered specification of predefined primary outcomes and analyses by the investigators as indicators of validity. Selective reporting of particular outcomes was taken as evidence for potential bias. Overall quality When assessing overall quality, the authors used simple approaches that include individual criteria, such as adequacy of allocation concealment, randomisation method, blinding to the intervention allocation, and selective reporting of results. Authors avoided scales with multiple items and complex scoring system because there are not supported by empirical evidence ( Schulz 1995), they do not provide more reliable assessments of quality (Juni 1999), and may carry a greater risk of confusing the quality of reporting with the validity of the study. Data extraction Two authors independently extracted data on characteristics of studies and patients, measurements, and results (outcomes); any discrepancy was discussed until consensus was reached. We also recorded in more detail, the names of the authors, journal and year of publication, country of origin, years of patient enrolment, number of patients randomised, number of patients analysed, reasons for differences between randomised and analysed participants, and number of arms and type of intervention(s) per arm, demographic characteristics in each arm, history of withdrawal symptoms, previous detoxification or withdrawal treatment, severity of alcohol withdrawal symptoms before therapy, time of pre-therapy evaluation, type of benzodiazepine(s), dose (daily and total) of benzodiazepine(s), number of sessions, duration and class (short-acting or long-acting) of benzodiazepine therapy, time, dose and duration of other therapies, and any supplementary medications used. In addition we also recorded information on the safety (potential harms) of the compared interventions with emphasis on discontinuations due to toxicity and benzodiazepine dependence as well as all severe, life-threatening, and serious adverse events. Finally, we determined whether each trial specified the mode of randomisation, blinding, allocation concealment and withdrawals per arm as well as who assessed outcomes in each trial. Data synthesis We performed meta-analysis when appropriate for each of the pre-specified outcomes. Both fixed and random effects models were used and primary results are given for random effects calculations. Continuous measures were summarized using weighted mean differences and binary outcomes were summarized using relative risks. Between-study heterogeneity was estimated with the chi square based Q statistic (considered statistically significant at p < 0.10) and was also expressed by the I-square estimates (considered significant at > 75%). Also, we tried to separate symptomtriggered from fixed schedule regimens. Calculations were performed using RevMan 4.2. For continuous measures with missing estimates of standard deviation per arm, we imputed the median standard deviation from the other available studies. For continuous measures evaluated during follow-up, we compared changes from baseline values. Meta-analysis was performed only for studies that had directly comparable interventions and used the same dichotomous outcomes or exactly the same rating scales for continuous outcome measures. For outcomes and comparisons where data were available from only one study, information could not be synthesized. However, this potentially useful information is shown in the Analyses. Following results are derived from quantitative synthesis and are divided into five main comparisons: Benzodiazepine versus Placebo, Benzodiazepine versus Other Drug, Different Benzodiazepines among themselves, Benzodiazepine + Other Drug versus Other Drug, and Benzodiazepine (fixed schedule) versus Benzodiazepine (symptom-triggered). R E S U L T S Description of studies See: Characteristics of included studies; Characteristics of excluded studies. 5
6 The electronic search strategies resulted in 660 records, which were screened by reading the titles and abstracts. Seventy-seven reports were considered appropriate for full-text scrutiny. Excluded studies We excluded 16 potentially eligible trial reports that were ineligible upon full-text scrutiny (Benuzzi 1967; Bowman 1966; Gallant 1969; Gerra 1991; Huber 1990; Lazarova 2003; Malmgren 1967; Mery 1979; Muller 1969; Myrick 2000; Rothstein 1973; Sampliner 1974; Sereny 1965; Shaffer 1968; Silpakit 1999; Thompson 1975), four duplicate or preliminary presentations ( Baumgartner 1988; Gillman 2002; Klett 1971; Malcolm 2000), and one that could not be retrieved in full text and its abstract did not provide relevant data (McGrath 1975). See Characteristics of excluded studies Included studies Fifty-six reports were considered eligible. One eligible report included two separate trials (Burroughs 1985a; Burroughs 1985b) according to initial severity of alcohol withdrawal, thus a total of 57 different trials that involved 4,275 participants were considered. Two eligible studies (Malcolm 2002a; Pena-Ramos 1979) involved 224 participants with previously published data on different outcomes. Thus, a total of 4,051 different patients were included in the analysed trials. See Characteristics of included studies Number of studies per type of comparison (1) Benzodiazepine versus placebo (No. = 8 studies) (2) Benzodiazepine versus other drug (No. = 34 studies) (3) Different benzodiazepines among themselves (No. = 13 studies) (4) Benzodiazepine combined with other drug versus that other drug (No. = 3 studies) (5) Fixed versus symptom-triggered schedule of a benzodiazepine (No. = 3 studies) Risk of bias in included studies All included studies were randomised, controlled trials. The randomisation method was described in 21 studies; randomisation was performed centrally in only seven trials (Burroughs 1985a; Burroughs 1985b; Daeppen 2002; Jauhar 2000; Malcolm 2002a; Malcolm 2002b; Radouco-Thomas 1989). The efforts for allocation concealment were not clarified in the majority of the studies. According to the published reports it did not appear that allocation was adequately concealed in 11 trials (Baumgartner 1991; Burroughs 1985a; Burroughs 1985b; Gillman 2004; Gillmer 1973; Golbert 1967; Lepola 1984; Lucht 2003; Overall 1973; Radouco-Thomas 1989; Runion 1978), while allocation was adequately concealed in only nine trials (Brown 1972; Daeppen 2002; Jauhar 2000; Kaim 1969; Kaim 1972; Malcolm 2002a; Malcolm 2002b; Spies 2003; Tubridy 1988). All the trials were described as double-blind except for one single-blind trial (Addolorato 1999) and two open-label trials (Brown 1972; Lucht 2003) and six studies that did not comment adequately on masking (Funderburk 1978; Golbert 1967; Lenzenhuber 1999; Longo 2002; Overall 1973; Spies 2003). Selective reporting of particular outcomes was more than common in the included studies. Effects of interventions Benzodiazepine versus Placebo Therapeutic success : Three trials (graph ), including a total of 112 randomised participants, addressed this outcome. Therapeutic success tended to be more common in the benzodiazepine-group (RR 1.40; 95% CI 0.87 to 2.27; p = 0.17; p = 0.03 for between-study heterogeneity). Alcohol withdrawal seizures: Three trials (graph ), including a total of 324 randomised participants, addressed this outcome. Benzodiazepines offered a significant benefit against seizures (RR 0.16; 95% CI 0.04 to 0.69; p = 0.01; p = 0.88 for betweenstudy heterogeneity). Number of withdrawals per arm: Three trials (graph ), including a total of 314 randomised participants, addressed this outcome. Number of withdrawals per arm tended to be less common among benzodiazepine-treated participants (RR 0.69; 95% CI 0.38 to 1.24; p = 0.22; p = 0.50 for between-study heterogeneity). Mortality : Of 8 trials (graph ) including a total of 480 randomised participants, none died. Discontinuation due to side effects: Two trials (graph ) addressed this outcome. No discontinuation due to side effects was seen among 53 benzodiazepine-treated participants, while one of 33 participants receiving placebo discontinued the treatment due to side effects. Benzodiazepine versus Other Drug CIWA-Ar score (change from baseline): (i) at 48 hours. Six trials (graphs and ), including a total of 403 randomised participants, addressed this outcome. Benzodiazepines were not more effective in reducing CIWA-Ar score at 48 hours compared to either other drugs (WMD -0.76; 95% CI to 0.36; p = 0.18; p = 0.67 for between-study heterogeneity) or anticonvulsants (WMD -0.73; 95% CI to 1.42; p = 0.51; p = 0.68 for between-study heterogeneity). (ii) at the end of treatment. Six trials (graphs and ), including a total of 403 randomised participants, addressed this outcome. No difference between benzodiazepines and other drugs was seen for CIWA-Ar score reduction at the end of treatment (WMD -0.05; 95% CI to 1.08; p = 0.93; p = 0.72 for between-study heterogeneity), while benzodiazepines tended to be less effective when compared to anticonvulsants (WMD -1.04; 95% CI to 1.38; p = 0.40; p = 0.87 for between-study heterogeneity). Doctor s global assessment (change from baseline) at the end of treatment: Data from three trials (graph ), including a total of 122 randomised participants, on this outcome showed that benzodiazepines were borderline less effective compared to other drugs (WMD -2.14; 95% CI to 0.01; p = 0.05; p = for between-study heterogeneity), but data were sparse. 6
7 Patient s global assessment (change from baseline) at the end of treatment: Data from three trials (graphs and ), including a total of 157 randomized participants, on this outcome showed that benzodiazepines tended to be more effective compared to either other drugs (WMD 4.95; 95% CI to 20.51; p = 0.53) or anticonvulsants (WMD 10.76; 95% CI to 32.81; p = 0.34). However, there was significant between-study heterogeneity in these analyses (p < ) and data were very sparse. Hamilton Anxiety Rating Scale (HARS) score (change from baseline): (i) at 48 hours. Two small trials (graph ), including a total of 83 randomised participants, addressed this outcome. There was a significant inferiority of benzodiazepines compared to other drugs (WMD -1.57; 95% CI to -0.60; p = 0.002; p = 0.74 for between-study heterogeneity). (ii) at the end of treatment. Three trials (graph ), including a total of 130 randomised patients, addressed this outcome. Benzodiazepines were significantly less effective compared to other drugs (WMD -2.44; 95% CI to -0.97; p = 0.001; p = 0.30 for between-study heterogeneity), but data were very sparse. Therapeutic success: Eight trials (graphs and ), including a total of 384 randomised patients, addressed this outcome. There was absolutely no difference in therapeutic success between benzodiazepines and either other drugs (RR 1.00; 95% CI 0.83 to 1.21; p = 0.99; p = for between-study heterogeneity) or anticonvulsants (RR 0.88; 95% CI 0.60 to 1.30; p = 0.51; p = for between-study heterogeneity) while 95% confidence intervals were narrow enough to suggest any clinically meaningful effect. Global doctor s assessment of efficacy: Four trials (graphs and ), including a total of 281 randomised patients, addressed this outcome. No difference between benzodiazepines and either other drugs (RR 1.04; 95% CI 0.98 to 1.10; p = 0.24; p = 0.69 for between-study heterogeneity) or anticonvulsants (RR 1.02; 95% CI 0.90 to 1.17; p = 0.74; p = 0.18 for between-study heterogeneity) was seen. Global patient s assessment of efficacy: Data from two trials (graph ), including a total of 140 randomised patients, showed no difference between benzodiazepines and other drugs (RR 1.05; 95% CI 0.98 to 1.11; p = 0.16; p = 0.73 for betweenstudy heterogeneity). Any success: Twelve trials (graphs , , and ), including a total of 667 randomised patients, addressed this outcome. There was no difference in success between benzodiazepines and either other drugs (RR 1.02; 95% CI 0.92 to 1.12; p = 0.75; p = 0.02 for between-study heterogeneity) or anticonvulsants (RR 1.00; 95% CI 0.87 to 1.16; p = 0.99; p = for between-study heterogeneity). No difference between long-acting benzodiazepines (RR 1.00; 95% CI 0.86 to 1.18; p = 0.95; p = for between-study heterogeneity) or short-acting benzodiazepines (RR 1.04; 95% CI 0.98 to 1.11; p = 0.21; p = 0.70 for between-study heterogeneity) and other drugs was seen. Alcohol withdrawal seizures: Eleven trials (graphs , , , and ), including a total of 1,139 randomised participants, addressed this outcome. There was a non-significant benefit against seizures of benzodiazepines compared to other drugs (RR 0.54; 95% CI 0.21 to 1.42; p = 0.21; p = 0.46 for between-study heterogeneity), but this difference was in the opposite direction when benzodiazepines were compared to anticonvulsants (RR 1.99; 95% CI 0.46 to 8.65; p = 0.36; p = 0.96 for between-study heterogeneity). Analysis of benzodiazepines versus non-anticonvulsants showed a significant benefit (RR 0.23; 95% CI 0.07 to 0.75; p = 0.02; p = 0.70 for betweenstudy heterogeneity). Long-acting benzodiazepines offered a nonsignificant benefit against seizures (RR 0.41; 95% CI 0.13 to1.28; p = 0.12; p = 0.43 for between-study heterogeneity), but this was not seen for the comparison of short-acting benzodiazepines vs. other drugs (RR 1.09; 95% CI 0.18 to 6.46; p = 0.92; p = 0.36 for between-study heterogeneity). The confidence intervals for both subgroup estimates were nevertheless very large and overlapping. Alcohol withdrawal delirium: Seven trials (graphs , , , and ), including a total of 752 randomised participants, addressed this outcome. There was a non-significant benefit against delirium of benzodiazepines versus other drugs (RR 0.48; 95% CI 0.14, 1.61; p = 0.23; p = 0.04 for between-study heterogeneity), but this was in the opposite direction for the comparison of benzodiazepines vs. anticonvulsants (RR 1.37; 95% 0.25, 7.37; p = 0.71; p = 0.13 for between-study heterogeneity). Analysis of benzodiazepines versus non-anticonvulsants showed a non-significant benefit (RR 0.32; 95% CI 0.06, 1.76; p = 0.19; p = 0.03 for between-study heterogeneity). Longacting benzodiazepines offered a non-significant benefit against delirium (RR 0.35; 95% CI 0.09 to 1.36; p = 0.13; p = 0.02 for between-study heterogeneity), while data for short-acting benzodiazepines versus another drug were limited to a single small study. Number of withdrawals per arm: Nineteen trials (graphs and ), including a total of 1,638 randomised participants, addressed this outcome. No difference in number of withdrawals per arm was seen when benzodiazepines were compared to either other drugs (RR 0.91; 95% CI 0.68, 1.23; p = 0.54; p = 0.90 for between-study heterogeneity) or anticonvulsants (RR 0.93; 95% CI 0.60 to 1.45; p = 0.75; p = 0.98 for between-study heterogeneity). Mortality: In 34 trials (graphs and ), two of 901 benzodiazepine-treated participants and five (one treated with an anticonvulsant) of 1,275 participants receiving other drug died. Side effects: Fifteen trials (graphs and ), including a total of 717 randomised participants, addressed this outcome. Benzodiazepine-treated participants had a slightly higher incidence of side-effects compared to patients receiving either other drugs (RR 1.23; 95% CI 0.92 to 1.63; p = 0.16; p = 0.69 for between-study heterogeneity) or anticonvulsants (RR 1.16; 95% CI 0.77 to 1.75; p = 0.47; p = 0.35 for between-study heterogeneity), but this didn t reach formal statistical significance. 7
8 Severe, life-threat ing side-effects: Eight trials (graphs and ), including a total of 386 randomised participants, addressed this outcome. Life-threating side-effects tended to be less common among benzodiazepine-treated participants compared to participants receiving other drugs (RR 0.85; 95% CI 0.19 to 3.82; p = 0.84; p = 0.38 for between-study heterogeneity), but this difference was in the opposite direction when benzodiazepines were compared to anticonvulsants (RR 1.45; 95% CI 0.19 to 11.24; p = 0.72; p = 0.65 for between-study heterogeneity). Discontinuation due to side effects: Ten trials (graphs and ) addressed this outcome. Three of 252 benzodiazepine-treated participants discontinued the treatment due to side effects, while 11 (7 treated with an anticonvulsant) of 369 participants receiving other drug did so. Different Benzodiazepines among themselves Thirteen trials (Adinoff 1994; Brown 1972; Jauhar 2000; Kolin 1981; Martin 1975; McLendon 1980; Mendels 1985; Miller 1984; O Brien 1983; Ritson 1986; Saletu 1983; Solomon 1983; Wilson 1985), including a total of 571 randomised participants, examined eight different comparisons of benzodiazepines among themselves for various outcomes. Limited data on scattered comparisons of various drugs in small studies were available. There was no conclusive evidence or even hints for superiority of specific drugs, but modest differences could have been missed due to limited data. Benzodiazepine+Other Drug versus Other Drug Three trials (Dion 1968; Sellers 1977; Spies 1996), including a total of 207 randomised participants, compared the combination of a benzodiazepine with another drug (magnesium sulphate, propranolol, haloperidol) versus this other drug for various outcomes. Very limited data were available, thus making quantitative synthesis not applicable. Benzodiazepine (fixed schedule) versus Benzodiazepine (symptom-triggered) Three trials (Daeppen 2002; Saitz 1994; Spies 2003), including a total of 262 randomised participants, compared fixed versus symptom-triggered schedules of a benzodiazepine (chlordiazepoxide, oxazepam, flunitrazepam) for various outcomes. There was a small and non-significant benefit of symptom-triggered regimens regarding CIWA-Ar score (change from baseline) at the end of treatment (WMD -0.51; 95% CI to 1.35; p = 0.59; p = 0.31 for between-study heterogeneity), therapeutic success (RR 0.88; 95% CI 0.52 to 1.52; p = 0.66; p = for between-study heterogeneity) and number of withdrawals per arm (RR 1.96; 95% CI 0.50 to 7.70; p = 0.33; p = 0.63 for between-study heterogeneity). The CIWA-Ar difference was formally significant at 48 hours (WMD -5.70; 95% CI to -0.38; p = 0.04) but was based on a single small study. Data on all other outcomes were very limited to perform any meaningful quantitative synthesis. D I S C U S S I O N This systematic review includes data from 57 RCTs with over 4,000 patients with alcohol withdrawal syndrome. Despite the considerable number of RCTs, the large variety of outcomes and rating scales limited considerably the ability to perform a quantitative synthesis of all available data. Benzodiazepines clearly offered a significant benefit against alcohol withdrawal seizures compared to placebo. This might suggest that their current status as first-line treatment for alcohol withdrawal syndrome is justified. Nevertheless, the available evidence did not suggest that benzodiazepines are clearly superior to other drugs with the exception of a possible superiority in seizure control when compared against non-anticonvulsants. Broadly defined success rates were very similar with benzodiazepines versus other drugs and the 95% confidence intervals even exclude any clinically meaningful differences in this regard. This was true for both short-acting and long-acting benzodiazepines. Differences between regimens in isolated small trials using more particular outcome measures should be interpreted very cautiously given the large number of outcomes in this field and the small sample size of the studies conducted therein. Nevertheless, even the limited data on such outcomes are not suggestive of any clear superiority of benzodiazepines. Benzodiazepines were less effective, if anything, compared to other drugs in reducing the severity of alcohol withdrawal symptoms, as indicated by change from baseline in doctor s global assessment score at the end of treatment and Hamilton Anxiety Rating Scale score at both 48 hours and the end of treatment in a few small trials. When compared to anticonvulsants, benzodiazepines tended to offer a non-significant benefit for change from baseline in the patient s global assessment score at the end of treatment, but also a non-significant increased risk for alcohol withdrawal seizures. Data on the comparisons of different benzodiazepines among themselves, benzodiazepine combined with other drug versus other drug, and fixed-schedule versus symptom-triggered regimens of benzodiazepines were very limited, thus making quantitative synthesis for various outcomes either not applicable or not very informative. Based on indirect comparisons, there is no strong evidence at the moment that particular benzodiazepines are more effective than others. The overall results need to be interpreted with caution, as bias cannot be excluded. Most trials were of very small sample size. Although randomisation was an inclusion criterion indicating some methodological quality for these studies, the method of randomisation was not usually described in sufficient detail in the published reports. Moreover, allocation concealment was usually unclear and information on follow-up was often missing. Furthermore, it was difficult to interpret comparisons of specific settings of treatment (inpatient or outpatient), because a large number of the analysed studies did not present sufficient background information so as to 8
9 allow a clear understanding of the treatment setting. We could not also examine dose-response effects since patients were not treated with even similar doses of various benzodiazepines across RCTs. Small trials are difficult to interpret in isolation, especially in the face of potential selective reporting of outcomes. Information on side-effects was not consistently reported in the trial reports. More detailed data on adverse effects would be important to record in these trials, since discontinuation due to sideeffects may affect the success of treatment. Moreover, data on side effects should be compared cautiously, as they were derived from patients with potentially different co-morbidity. Patients with severe medical conditions, such as hepatic, heart or lung disease, were often excluded from these trials. However, these patients may be more susceptible to various adverse effects of benzodiazepines. The extremely small mortality rate in all these studies is reassuring, but data on other harms-related outcomes are sparse and fragmented. This important deficiency of the benzodiazepine literature needs to be highlighted for improving future clinical research efforts in this field. Overall, the small sample size of published RCTs and lack of detailed information on various outcomes illustrate a need for larger, well-designed studies in this field. These studies should be limited to more important efficacy variables and consistency on rating continuous outcomes with the same scales should also be achieved among researchers. A U T H O R S C O N C L U S I O N S Implications for practice Benzodiazepines are effective against alcohol withdrawal symptoms, in particular seizures, when compared to placebo. It is not possible to draw very precise conclusions about the relative effectiveness and safety of benzodiazepines against other drugs in alcohol withdrawal, because of the large heterogeneity of the trials both in interventions and assessment of outcomes. Nevertheless, the available data do not show differences between benzodiazepines and other drugs in broadly defined success rates. Data on potential harms are sparse and fragmented. Implications for research Although a significant number of trends has emerged, most of these were small and the data for most outcomes did not reach statistical significance, indicating the need for larger, well-designed studies in this field. These studies should be limited to few, important efficacy variables such as severity of the alcohol withdrawal syndrome, incidence of seizures and delirium tremens, side effects and mortality. Consistency on rating continuous outcomes in the same scales should also be achieved in order to obtain comparable information from all relevant studies. A C K N O W L E D G E M E N T S We thank Dr. Despina Contopoulos-Ioannidis for providing helpful assistance with data extraction and Dr. Athina Tatsioni for article retrieval. R E F E R E N C E S References to studies included in this review Addolorato 1999 {published data only} Addolorato G, Balducci G, Capristo E, Attilia ML, Taggi F, Gasbarrini G, et al.gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomised comparative study versus benzodiazepine. Alcoholism, Clinical and Experimental Research 1999;23(10): Adinoff 1994 {published data only} Adinoff B. Double-blind study of alprazolam, diazepam, clonidine, and placebo in the alcohol withdrawal syndrome: preliminary findings. Alcoholism, Clinical and Experimental Research 1994;18(4): Ansoms 1991 {published data only} Ansoms S, Lebon O, Pelc I, Cabri C, Poels R. Zopiclone or lormetazepam in the treatment of insomnia and the effect on behavior and mood in patients during the post alcoholism withdrawal period. Current Therapeutic Research, Clinical & Experimental 1991; 49(1): Anton 1997 {published data only} Anton RF, Kranzler HR, McEvoy JP, Moak DH, Bianca R. A doubleblind comparison of abecarnil and diazepam in the treatment of uncomplicated alcohol withdrawal. Psychopharmacology (Berl) 1997; 131(2): Bailly 1992 {published data only} Bailly D, Servant D, Blandin N, Beuscart R, Parquet PJ. Effects of beta-blocking drugs in alcohol withdrawal: a double-blind comparative study with propranolol and diazepam. Biomedicine and Pharmacotherapy 1992;46(9): Baumgartner 1987 {published data only} Baumgartner GR, Rowen RC. Clonidine vs chlordiazepoxide in the management of acute alcohol withdrawal syndrome. Archives of Internal Medicine 1987;147(7): Baumgartner 1991 {published data only} Baumgartner GR, Rowen RC. Transdermal clonidine versus chlordiazepoxide in alcohol withdrawal: a randomised, controlled clinical trial. South African Medical Journal 1991;84(3):
Benzodiazepines for alcohol withdrawal (Review)
Amato L, Minozzi S, Vecchi S, Davoli M This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2010, Issue 3 http://www.thecochranelibrary.com
More informationBackground. Population/Intervention(s)/Comparison/Outcome(s) (PICO) List of the systematic reviews identified by the search process
updated 2012 Treatment of alcohol withdrawal delirium Q3: In the treatment of alcohol withdrawal delirium, are benzodiazepines or antipsychotics safe and effective when compared to a placebo/appropriate
More informationOutpatient Treatment of Alcohol Withdrawal. Daniel Duhigg, DO, MBA
Outpatient Treatment of Alcohol Withdrawal Daniel Duhigg, DO, MBA DSM V criteria for Alcohol Withdrawal A. Cessation or reduction of heavy/prolonged alcohol use B. 2 or more of the following in hours to
More informationBackground. Population/Intervention(s)/Comparison/Outcome(s) (PICO) Management of alcohol withdrawal
updated 2012 Management of alcohol withdrawal Q2: What interventions are safe and effective for the management of alcohol withdrawal, including treatment for alcohol withdrawal seizures and prevention
More informationAlcohol Withdrawal Recognition and Treatment
Alcohol Withdrawal Recognition and Treatment Thomas Meyer BS EMS, MICP SREMSC Page 1 Purpose As EMTs a mantle of responsibility is placed upon you to ensure the safety and well-being of those in your charge
More informationAlcohol Withdrawal Syndromes
Alcohol Withdrawal Syndromes Should You Treat This Patient s Alcohol Withdrawal With Benzodiazepines?! Meta-analysis of RCTs of benzodiazepines for the treatment of alcohol withdrawal! 11 RCTs identified,
More informationAlcohol Withdrawal. Introduction. Blood Alcohol Concentration. DSM-IV Criteria/Alcohol Abuse. Pharmacologic Effects of Alcohol
Pharmacologic Effects of Alcohol Alcohol Withdrawal Kristi Theobald, Pharm.D., BCPS Therapeutics III Fall 2003 Inhibits glutamate receptor function (NMDA receptor) Inhibits excitatory neurotransmission
More informationCase. History of psoriatic arthritis, htn, essential tremor Meds: propranolol, etodolac, etanercept No history of prior psychiatric disease.
Case 48 year old man admitted complaining of hallucinations. Mild hallucinations for a year. Worsened tremor for 3 weeks and then markedly worse hallucinations last 2 days History of psoriatic arthritis,
More informationAlcohol Withdrawal Syndrome & CIWA Assessment
Alcohol Withdrawal Syndrome & CIWA Assessment Alcohol Withdrawal Syndrome is a set of symptoms that can occur when an individual reduces or stops alcoholic consumption after long periods of use. Prolonged
More informationSymptom Based Alcohol Withdrawal Treatment
Symptom Based Alcohol Withdrawal Treatment -Small Rural Hospital- Presenter CDR Dwight Humpherys, DO dwight.humpherys@ihs.gov Idaho State University Baccalaureate Nursing Program Lake Erie College of Osteopathic
More informationGamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses (Review)
Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses (Review) Leone MA, Vigna-Taglianti F, Avanzi G, Brambilla R, Faggiano F This is a reprint of a Cochrane review,
More informationQ4: Are acamprosate, disulfiram and naltrexone safe and effective in preventing relapse in alcohol dependence in nonspecialized health care settings?
updated 2012 Preventing relapse in alcohol dependent patients Q4: Are acamprosate, disulfiram and naltrexone safe and effective in preventing relapse in alcohol dependence in nonspecialized health care
More informationPhenobarbital in Severe Alcohol Withdrawal Syndrome. Jordan Rowe Pharm.D. Candidate UAMS College of Pharmacy
Phenobarbital in Severe Alcohol Withdrawal Syndrome Jordan Rowe Pharm.D. Candidate UAMS College of Pharmacy Disclosure: No relevant financial relationship exists. Objectives 1. Describe the pathophysiology
More informationA COMPARATIVE STUDY OF EFFICACY & TOLERABILITY OF LORAZEPAM AND GABAPENTIN IN THE TREATMENT OF ALCOHOL WITHDRAWAL SYNDROME
A COMPARATIVE STUDY OF EFFICACY & TOLERABILITY OF LORAZEPAM AND GABAPENTIN IN THE TREATMENT OF ALCOHOL WITHDRAWAL SYNDROME Dr. Ashutosh Chourishi,* Dr. O.P. Raichandani**, Dr. Sunita Chandraker***, Dr.
More informationALCOHOL DETOXIFICATION (IN-PATIENTS) PRESCRIBING GUIDELINE
ALCOHOL DETOXIFICATION (IN-PATIENTS) PRESCRIBING GUIDELINE Authors Sponsor Responsible committee Ratified by Consultant Psychiatrist; Pharmacist Team Manager Medical Director Medicines Management Group
More informationIf several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form.
General Remarks This template of a data extraction form is intended to help you to start developing your own data extraction form, it certainly has to be adapted to your specific question. Delete unnecessary
More informationHow To Treat Alcohol Withdrawal In The Elderly
ALCOHOL ABUSE AND WITHDRAWAL SYNDROME IN THE ELDERLY Colin Muscat Family Medicine Case 90 year old Female Lives with son on vacation Admitted for FTT Consult -? GARP Develops increasing confusion during
More informationAlcohol Dependence and Motivational Interviewing
Alcohol Dependence and Motivational Interviewing Assessment of Alcohol Misuse Checklist Establish rapport patients are often resistant Longitudinal history of alcohol use Assess additional drug use Establish
More informationAlcohol and nicotine are widely abused substances and are often used together One study showed that 15% of patients visiting a primary care practice
Dr IM Joubert Alcohol and nicotine are widely abused substances and are often used together One study showed that 15% of patients visiting a primary care practice for any reason had either an at-risk pattern
More informationSPECIFICATION FOR THE LOCAL COMMISSIONED SERVICE FOR THE MANAGEMENT ALCOHOL MISUSE
SPECIFICATION FOR THE LOCAL COMMISSIONED SERVICE FOR THE MANAGEMENT OF ALCOHOL MISUSE Date: March 2015 1 1. Introduction Alcohol misuse is a major public health problem in Camden with high rates of hospital
More informationMOH CLINICAL PRACTICE GUIDELINES 2/2008 Prescribing of Benzodiazepines
MOH CLINICL PRCTICE GUIELINES 2/2008 Prescribing of Benzodiazepines College of Family Physicians, Singapore cademy of Medicine, Singapore Executive summary of recommendations etails of recommendations
More informationAnticonvulsants for alcohol withdrawal (Review)
Minozzi S, Amato L, Vecchi S, Davoli M This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2010, Issue 3 http://www.thecochranelibrary.com
More informationPhilip Moore DO, Toxicology Fellow, PinnacleHealth Toxicology Center Joanne Konick-McMahan RN MSRN, Staff RN, PinnacleHealth
Philip Moore DO, Toxicology Fellow, PinnacleHealth Toxicology Center Joanne Konick-McMahan RN MSRN, Staff RN, PinnacleHealth I. II. Background A. AWS can occur in anyone who consumes alcohol B. Risk correlates
More informationGP Drug & Alcohol Supplement No.7 May 1997
GP Drug & Alcohol Supplement No.7 May 1997 This is the seventh of the monthly Drug and Alcohol Supplements prepared for Central Coast GPs. Detoxification from Alcohol Dr Tony Gill Introduction The management
More informationNICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.
bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.
More informationCochrane Review: Psychological treatments for depression and anxiety in dementia and mild cognitive impairment
23 rd Alzheimer Europe Conference St. Julian's, Malta, 2013 Cochrane Review: Psychological treatments for depression and anxiety in dementia and mild cognitive impairment Orgeta V, Qazi A, Spector A E,
More information33 % of whiplash patients develop. headaches originating from the upper. cervical spine
33 % of whiplash patients develop headaches originating from the upper cervical spine - Dr Nikolai Bogduk Spine, 1995 1 Physical Treatments for Headache: A Structured Review Headache: The Journal of Head
More informationAdjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.
Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,
More informationNalmefene for reducing alcohol consumption in people with alcohol dependence
Nalmefene for reducing alcohol consumption in people with alcohol dependence Issued: November 2014 guidance.nice.org.uk/ta325 NICE has accredited the process used by the Centre for Health Technology Evaluation
More informationPain Medication Taper Regimen Time frame to taper off 30-60 days
Pain Medication Taper Regimen Time frame to taper off 30-60 days Medication to taper Taper Regimen Comments Methadone Taper by no more than 25% Morphine Taper by no more than 25% Tramadol Taper by no more
More informationAlcohol withdrawal A challenge in caring for patients after heart surgery
Abteilung Praxisentwicklung Pflege Alcohol withdrawal A challenge in caring for patients after heart surgery Wolfgang Hasemann, RN, PhD Deborah Leuenberger, MScN.cand. June 2015 Content Alcohol consumption
More informationSymptom-Triggered Alcohol Detoxification: A Guideline for use in the Clinical Decisions Unit of the Emergency Department.
Symptom-Triggered Alcohol Detoxification: A Guideline for use in the Clinical Decisions Unit of the Emergency Department. Dr Eugene Cassidy, Liaison Psychiatry; Dr Io har O Sulliva, E erge cy Department,
More informationNew York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery
New York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery USING THE 48 HOUR OBSERVATION BED USING THE 48 HOUR OBSERVATION BED Detoxification
More informationHugh Myrick, M.D., and Raymond F. Anton, M.D.
Treatment of Alcohol Withdrawal Hugh Myrick, M.D., and Raymond F. Anton, M.D. Appropriate treatment of alcohol withdrawal (AW) can relieve the patient s discomfort, prevent the development of more serious
More information75-09.1-08-02. Program criteria. A social detoxi cation program must provide:
CHAPTER 75-09.1-08 SOCIAL DETOXIFICATION ASAM LEVEL III.2-D Section 75-09.1-08-01 De nitions 75-09.1-08-02 Program Criteria 75-09.1-08-03 Provider Criteria 75-09.1-08-04 Admission and Continued Stay Criteria
More informationBenzodiazepines: A Model for Central Nervous System (CNS) Depressants
Benzodiazepines: A Model for Central Nervous System (CNS) Depressants Objectives Summarize the basic mechanism by which benzodiazepines work in the brain. Describe two strategies for reducing and/or eliminating
More informationAcute alcohol withdrawal
A NICE pathway brings together all NICE guidance, quality standards and materials to support implementation on a specific topic area. The pathways are interactive and designed to be used online. This pdf
More informationBiostat Methods STAT 5820/6910 Handout #6: Intro. to Clinical Trials (Matthews text)
Biostat Methods STAT 5820/6910 Handout #6: Intro. to Clinical Trials (Matthews text) Key features of RCT (randomized controlled trial) One group (treatment) receives its treatment at the same time another
More informationGUIDELINES FOR COMMUNITY ALCOHOL DETOXIFICATION IN SHARED CARE
GUIDELINES FOR COMMUNITY ALCOHOL DETOXIFICATION IN SHARED CARE Dr Millicent Chikoore MBBS MRCPsych Dr O Lagundoye MBBS MRCPsych Community based alcohol detoxification is a safe and effective option for
More informationDevelopment and Implementation of an Evidence-Based Alcohol Withdrawal Order Set. Kathleen Lenaghan MSN, RN-BC
Development and Implementation of an Evidence-Based Alcohol Withdrawal Order Set Kathleen Lenaghan MSN, RN-BC 1 2 Genesis Medical Center Davenport, Iowa Objectives Identify the process of developing and
More informationINTOXICATED PATIENTS AND DETOXIFICATION
VAMC Detoxification Decision Tree Updated May 2006 INTOXICATED PATIENTS AND DETOXIFICATION Patients often present for evaluation of substance use and possible detoxification. There are certain decisions
More information1. According to recent US national estimates, which of the following substances is associated
1 Chapter 36. Substance-Related, Self-Assessment Questions 1. According to recent US national estimates, which of the following substances is associated with the highest incidence of new drug initiates
More informationCritical appraisal of systematic reviews
Critical appraisal of systematic reviews Abalos E, Carroli G, Mackey ME, Bergel E Centro Rosarino de Estudios Perinatales, Rosario, Argentina INTRODUCTION In spite of the increasingly efficient ways to
More informationTHE BASICS. Community Based Medically Assisted Alcohol Withdrawal. World Health Organisation 2011. The Issues 5/18/2011. RCGP Conference May 2011
RCGP Conference May 2011 Community Based Medically Assisted Alcohol Withdrawal THE BASICS An option for consideration World Health Organisation 2011 Alcohol is the world s third largest risk factor for
More informationSupported Alcohol Withdrawal Treatment Information
Supported Alcohol Withdrawal Treatment Information Alcohol Liaison Service What is Alcohol Withdrawal Syndrome? If you are dependent on alcohol and suddenly stop drinking or you are admitted to hospital
More informationChapter 7. Screening and Assessment
Chapter 7 Screening and Assessment Screening And Assessment Starting the dialogue and begin relationship Each are sizing each other up Information gathering Listening to their story Asking the questions
More informationChapter 5 Alcohol withdrawal management
Chapter 5 Alcohol withdrawal management Alcohol Withdrawal Syndrome: Clinical Presentation This section discusses the clinical signs and symptoms, onset and duration, and common complications of alcohol
More informationTITLE: Acupuncture for Management of Addictions Withdrawal: Clinical Effectiveness
TITLE: Acupuncture for Management of Addictions Withdrawal: Clinical Effectiveness DATE: 09 October 2008 RESEARCH QUESTION: What is the clinical effectiveness of auricular acupuncture in the management
More informationDEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE
1 DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE ASSESSMENT/PROBLEM RECOGNITION 1. Did the staff and physician seek and document risk factors for depression and any history of depression? 2. Did staff
More informationGeneral Internal Medicine Grand Rounds. Julie Taub, MD Denver Health & Hospital Authority, Denver CO
The Treatment of Acute Alcohol Withdrawal General Internal Medicine Grand Rounds February 14, 2012 Julie Taub, MD Denver Health & Hospital Authority, Denver CO Pharmacology Ethanol Benzodiazepines Chlormethiazole
More informationAdoption by CHMP for release for consultation November 2010. End of consultation (deadline for comments) 31 March 2011
1 2 3 November 2010 EMA/759784/2010 Committee for Medicinal Products for Human Use 4 5 6 7 Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and
More informationSummary 1. Comparative-effectiveness
Cost-effectiveness of Delta-9-tetrahydrocannabinol/cannabidiol (Sativex ) as add-on treatment, for symptom improvement in patients with moderate to severe spasticity due to MS who have not responded adequately
More informationTITLE: Cannabinoids for the Treatment of Post-Traumatic Stress Disorder: A Review of the Clinical Effectiveness and Guidelines
TITLE: Cannabinoids for the Treatment of Post-Traumatic Stress Disorder: A Review of the Clinical Effectiveness and Guidelines DATE: 27 June 2012 CONTEXT AND POLICY ISSUES In 2009, CADTH reviewed the clinical
More informationHow To Know If You Should Be Treated
Comprehensive ehavioral Care, Inc. delivery system that does not include sufficient alternatives to a particular LOC and a particular patient. Therefore, CompCare considers at least the following factors
More informationPROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain
P a g e 1 PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain Clinical Phase 4 Study Centers Study Period 25 U.S. sites identified and reviewed by the Steering Committee and Contract
More informationAssessment and Management of Opioid, Benzodiazepine, and Sedative-Hypnotic Withdrawal
Assessment and Management of Opioid, Benzodiazepine, and Sedative-Hypnotic Withdrawal Roger Cicala, M. D. Assistant Medical Director Tennessee Physician s Wellness Program Step 1 Don t 1 It is legal in
More informationEmergency Room Treatment of Psychosis
OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different
More informationIn the United States, alcohol is the most commonly abused. Alcohol Withdrawal. Review Article
Review Article Alcohol Withdrawal Anton Manasco, BS, Shannon Chang, MD, Joseph Larriviere, MD, L. Lee Hamm, MD, and Marcia Glass, MD Abstract: Alcohol withdrawal is a common clinical condition that has
More informationAlcohol withdrawal syndromes in the intensive care unit
本 檔 僅 供 內 部 教 學 使 用 檔 案 內 所 使 用 之 照 片 之 版 權 仍 屬 於 原 期 刊 公 開 使 用 時, 須 獲 得 原 期 刊 之 同 意 授 權 Alcohol withdrawal syndromes in the intensive care unit MaryClare Sarff, MD; Jeffrey A. Gold, MD Crit Care Med 2010
More informationAlcohol Withdrawal Syndrome. Jeffrey P Schaefer MSc MD FRCPC GI Emergencies Update October 14, 2007 http:dr.schaeferville.com
Alcohol Withdrawal Syndrome Jeffrey P Schaefer MSc MD FRCPC GI Emergencies Update October 14, 2007 http:dr.schaeferville.com Objectives Alcohol Intoxication Take-Aways diagnosis avoid mis-diagnosis management
More informationBackground. Population/Intervention(s)/Comparator/Outcome(s) (PICO)
updated 2012 Role of anticholinergic medications in patients requiring long-term antipsychotic treatment for psychotic disorders Q6: In individuals with psychotic disorders (including schizophrenia) who
More informationAlcohol screening and brief intervention in primary care: no evidence of efficacy for dependence
Systematic review: Alcohol screening and brief intervention in primary care: no evidence of efficacy for dependence Richard Saitz MD, MPH, FACP, FASAM Professor of Medicine & Epidemiology Boston University
More informationSUBSTANCE USE DISORDER SOCIAL DETOXIFICATION SERVICES [ASAM LEVEL III.2-D]
SUBSTANCE USE DISORDER SOCIAL DETOXIFICATION SERVICES [ASAM LEVEL III.2-D] I. Definitions: Detoxification is the process of interrupting the momentum of compulsive drug and/or alcohol use in an individual
More informationUpdate and Review of Medication Assisted Treatments
Update and Review of Medication Assisted Treatments for Opiate and Alcohol Use Disorders Richard N. Whitney, MD Medical Director Addiction Services Shepherd Hill Newark, Ohio Medication Assisted Treatment
More information2.6.4 Medication for withdrawal syndrome
.6.3 Self-medication Self-medication presents a risk during alcohol withdrawal, particularly when there is minimal supervision (low level and medium level 1 settings). Inform patients of the risk of selfmedication
More informationAlcohol intervention programs in other countries
Alcohol intervention programs in other countries Assist. Prof. Dr. Suttiporn Janenawasin Siriraj Hosp. Mahidol Univ. A Major Task for Drug Treatment is Changing Brains Back! The Most Effective Treatment
More informationThese changes are prominent in individuals with severe disorders, but also occur at the mild or moderate level.
Substance-Related Disorders DSM-V Many people use words like alcoholism, drug dependence and addiction as general descriptive terms without a clear understanding of their meaning. What does it really mean
More informationAssisted alcohol withdrawal
A NICE pathway brings together all NICE guidance, quality standards and materials to support implementation on a specific topic area. The pathways are interactive and designed to be used online. This pdf
More informationAlcohol Liaison Service. Alcohol Withdrawal. Information
Alcohol Liaison Service Alcohol Withdrawal Information Alcohol withdrawal If you are dependent on alcohol and suddenly stop drinking, there are a series of symptoms that you may experience. These include:
More informationAssessment and management of alcohol dependence and withdrawal in the acute hospital
Assessment and management of alcohol dependence and withdrawal in the acute hospital Concise guidance to good practice series June 01 CONCISE GUIDANCE Clinical Medicine 01, Vol 1, No : 71 Assessment Main
More informationDrugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author
Version History Policy Title Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further
More informationVersion 2 This guideline describes how to manage patients who are showing signs and symptoms of alcohol withdrawal and Wernicke s Encephalopathy.
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality A Guideline for the Management of Acute Alcohol Withdrawal
More informationIn 1992, approximately 13.8 million
Alcohol Withdrawal Syndrome MAX BAYARD, M.D., JONAH MCINTYRE, M.D., KEITH R. HILL, M.D., and JACK WOODSIDE, JR., M.D. East Tennessee State University James H. Quillen College of Medicine, Johnson City,
More informationClinical Criteria 4.201 Inpatient Medical Withdrawal Management 4.201 Substance Use Inpatient Withdrawal Management (Adults and Adolescents)
4.201 Inpatient Medical Withdrawal Management 4.201 Substance Use Inpatient Withdrawal Management (Adults and Adolescents) Description of Services: Inpatient withdrawal management is comprised of services
More informationAlcohol Abuse and Addiction Management Protocol
Alcohol Abuse and Addiction Management Protocol All Team Members: Patient Self-Management Education and Support Alcohol is the most commonly abused drug in the United States. About 18 million people in
More informationCare Management Council submission date: August 2013. Contact Information
Clinical Practice Approval Form Clinical Practice Title: Acute use of Buprenorphine for the Treatment of Opioid Dependence and Detoxification Type of Review: New Clinical Practice Revisions of Existing
More informationTreatment of seizures in multiple sclerosis (Review)
Koch MW, Polman SKL, Uyttenboogaart M, De Keyser J This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 009, Issue 3 http://www.thecochranelibrary.com
More informationORIGINAL INVESTIGATION. Symptom-Triggered vs Fixed-Schedule Doses of Benzodiazepine for Alcohol Withdrawal
Symptom-Triggered vs Fixed-Schedule Doses of Benzodiazepine for Alcohol Withdrawal A Randomized Treatment Trial ORIGINAL INVESTIGATION Jean-Bernard Daeppen, MD; Pascal Gache, MD; Ulrika Landry, BA; Eva
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. This online publication has been corrected. The corrected
More informationFor Efficacy of Diazepam and Baclofen In The Treatment Of Alcohol Withdrawal Syndrome.. J Pharm Biomed Sci 2014; 04(06):482-488.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL SCIENCES Jhanwar A., Patidar OP., Sharma RN, Chourishi A., Jain A., A Double Blind Study For Efficacy of Diazepam and Baclofen In The Treatment Of Alcohol Withdrawal
More informationBENZODIAZEPINE CONSIDERATIONS IN WORKERS COMPENSATION: IMPLICATIONS FOR WORK DISABILITY AND CLAIM COSTS By: Michael Erdil MD, FACOEM
3 rd Quarter 2015 BENZODIAZEPINE CONSIDERATIONS IN WORKERS COMPENSATION: IMPLICATIONS FOR WORK DISABILITY AND CLAIM COSTS By: Michael Erdil MD, FACOEM Introduction Benzodiazepines, sometimes called "benzos",
More informationALCOHOL AND OTHER DRUG WITHDRAWAL: PRACTICE GUIDELINES
ALCOHOL AND OTHER DRUG WITHDRAWAL: PRACTICE GUIDELINES 2009 Pauline Kenny Amy Swan Lynda Berends Linda Jenner Barbara Hunter Janette Mugavin CHAPTER 12: BENZODIAZEPINE WITHDRAWAL 12 BENZODIAZEPINES These
More informationBenzodiazepine Detoxification and Reduction of Long term Use
Benzodiazepine Detoxification and Reduction of Long term Use Malcolm Lader 1 Model of general drug misuse and dependence. Tactical interventional options Social dimension Increasing breaking of social
More informationImmunex Corporation Novantrone (Mitoxantrone HCL) P&CNS Advisory Committee Briefing Document. Page 020
Page 020 4.0 Efficacy of Mitoxantrone in Multiple Sclerosis The efficacy of mitoxantrone in MS was demonstrated in two well-designed, randomized trials: Studies 901 and 902. The study design and efficacy
More informationThinkTwice! Treating Alcohol Dependence with Topiramate: A Critical Appraisal Learning Activity JOURNAL ARTICLE TEI PLAIN LANGUAGE ANTHOLOGY
JOURNAL ARTICLE Transformed into part of a plain language anthology Treating Alcohol Dependence with Topiramate: A Critical Appraisal Learning Activity Abstract: This study set out to test a drug, topiramate,
More informationHow To Screen For Alcohol Dependence
Commonwealth of Massachusetts Board of Registration in Medicine Quality and Patient Safety Division Advisory Alcohol Screening and Management Protocols July 2013 Background The Quality and Patient Safety
More informationBorderline personality disorder
Borderline personality disorder Treatment and management Issued: January 2009 NICE clinical guideline 78 guidance.nice.org.uk/cg78 NICE 2009 Contents Introduction... 3 Person-centred care... 5 Key priorities
More informationTITLE: Cannabinoids for the Treatment of Post-Traumatic Stress Disorder: A Review of the Clinical Effectiveness and Guidelines
TITLE: Cannabinoids for the Treatment of Post-Traumatic Stress Disorder: A Review of the Clinical Effectiveness and Guidelines DATE: 01 December 2009 CONTEXT AND POLICY ISSUES: Post-traumatic stress disorder
More informationRULES OF THE TENNESSEE DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIES
RULES OF THE TENNESSEE DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIES CHAPTER 0940-05-47 MINIMUM PROGRAM REQUIREMENTS FOR ALCOHOL AND DRUG OUTPATIENT DETOXIFICATION TREATMENT FACILITIES TABLE
More informationRunning head: BEST TREATMENT FOR ALCOHOL WITHDRAWAL SYNDROME 1
1 Best Treatment for Alcohol Withdrawal Syndrome Kathryn Obert Auburn University School of Nursing 2 Abstract Alcoholism is defined as a pattern of uncontrolled drinking leading to medical, legal, and
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PDP IBT Inj - Vivitrol Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Opiate Antagonist Client: 2007 PDP IBT Inj Approval Date: 2/20/2007
More informationBreast cancer treatment for elderly women: a systematic review
Breast cancer treatment for elderly women: a systematic review Gerlinde Pilkington Rumona Dickson Anna Sanniti Funded by the NCEI and POI Elderly people less likely to receive chemotherapy than younger
More informationCritical Appraisal of Article on Therapy
Critical Appraisal of Article on Therapy What question did the study ask? Guide Are the results Valid 1. Was the assignment of patients to treatments randomized? And was the randomization list concealed?
More informationHow To Work With A Comorbidity
Audit of Alcohol Detoxification Prescribing Observatory for Mental Health (POMH-UK) Regional Event Wakefield 4th December 2013 definition and guidance Duncan Raistrick Leeds Addiction Unit Detoxification
More informationPrepared by:jane Healey (Email: janie_healey@yahoo.com) 4 th year undergraduate occupational therapy student, University of Western Sydney
1 There is fair (2b) level evidence that living skills training is effective at improving independence in food preparation, money management, personal possessions, and efficacy, in adults with persistent
More informationADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines - 2015
The Clinical Level of Care Guidelines contained on the following pages have been developed as a guide to assist care managers, physicians and providers in making medical necessity decisions about the least
More informationResidential Sub-Acute Detoxification Guidelines
I. Background Information A. Definition of Detoxification Residential Sub-Acute Detoxification Guidelines SAMSA s TIP #45, Detoxification and Substance Abuse Treatment: Treatment Improvement Protocols
More informationReview of Pharmacological Pain Management
Review of Pharmacological Pain Management CHAMP Activities are possible with generous support from The Atlantic Philanthropies and The John A. Hartford Foundation The WHO Pain Ladder The World Health Organization
More informationMaintenance of abstinence in alcohol dependence
Shared Care Guideline for Prescription and monitoring of Acamprosate Calcium Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist, Alcohol Services Dr Donnelly
More information